Stay updated on Epacadostat Plus Pembrolizumab in Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Epacadostat Plus Pembrolizumab in Gastric Cancer Clinical Trial page.

Latest updates to the Epacadostat Plus Pembrolizumab in Gastric Cancer Clinical Trial page
- Check6 days agoChange DetectedThe page revision label was updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedGastric cancer is now listed as a condition term, and a Genetic and Rare Diseases Information Center resource has been added under Resources.SummaryDifference0.2%

- Check34 days agoChange DetectedDifference0.4%

- Check41 days agoChange DetectedAdded a government funding lapse notice regarding NIH operations and updated the page revision to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedAdded a glossary toggle (Show glossary). Updated metadata labels, including a new revision tag (v3.4.0) and lines such as 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 (minor metadata update; content unaffected). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Epacadostat Plus Pembrolizumab in Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Epacadostat Plus Pembrolizumab in Gastric Cancer Clinical Trial page.